Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Defo worth a punt at this level…..GLA
Up 32.65%.
Astrazeneca contract!
One can only assume that if this trial is successful it will open ANGLE up to the full AstraZeneca pipeline which is 10's of thousands of patients needing multiple ANGLE test kits...the revenue could be company making!!
Also a big sign of confidence that Astra allowed their name to be used in the RNS they're usually very discreet so it shows confidence that they're happy to be associated with ANGLE. This is incredible news!!
Off now let the rampers do the work for me cya!
Agree need to be two faced at this game never let the idiots know exactly which side of the fence you are playing on..😉
TwoGood2Die you'll be wasting away your precious day here today trying to talk this down. Go outside and enjoy some fresh air. Maybe it will cleanse your soul of all the bitterness your carry inside.
I'm sorry to tell you but your little mouse voice has no impact on the share price here. So no use squeaking any further.
The £150k is simply for the development. It's the revenue that comes after that which counts
I am tempted to but at open and play the ramping game. Played well you make good money on this stock.
'Lie' in 🥕 was it forgot to set the alarm ⏰️ clock lol!
AstraZeneca agreement !
https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-astrazeneca-edeymgqdtcshqde.html
Agree Pump & Dump III
Where's 🥕?
Too busy dumping lol!
£150k is hopeless.
However, i get how this plays out.
So i reckon this will hit 25p-30p on news like this.
But then we will come back to where we started.
Money to be made if you are brave and quick!
IMHO
Is this deal smaller that the one with Japan's top 3 Pharma I think that was more around £250k mark in size from memory..
These are really tiny deals looking like it's being over ramped by Newland notice the spin around the size of the end market not the likely future deal pipeline with AZ..
Could be being over egged as the financials are going to be diasterous on the share price with concerns over an impending cash placement as that £6m additional revenues target to meet Q2 2025 cash runway extension vaporises!..
£150k doesn't even dent the £6m revenues needed feels more like Newland style spin prior to poor financials release than having any solid commercial substance to it!
Fair points from some people, but I know a "foot in the door" when I see one. ;)
We will all see how this pans out.
Mibb
Brief spike then falls back when financial results released this week?
Not the same area as the patents. This is an assay
20p could be hit today
Understand this mornings RNS is positive and contains price senstive infornation but its only £150k so won't last long and the value of the commercial deal is strangely very low....Us this mornings RNS designed to temper fall out expected with the poor financial results and try to stabalise the share price in advance of a cash placement?
NOT a lot but look who its with
Not so sure about that could say the same for the deal with the Japanese pharma...
Could be a another sharevprice spike to 35p and who knows may hang around sub 20's...
Financial results won't be pretty that's for sure and the deal is just £150k which feels oddly very low!
So 2 or 3 days after getting the patents, AZ make a move already, getting in first? This is basically an early stage takeover move. Could have been anyone, Pfizer, GSK etc.
Looks like 🥕's camping outside Astra Zenica head office might of had some effect lol...😉😅🤣😂!
This is surely going to go nuts today?
NEW COMMERCIAL AGREEMENT WITH LARGE PHARMA
ANGLE signs agreement to tailor existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response ("DDR") assay for the detection of micronuclei in CTCs as a measure of DDR.
Under the agreement, ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response. Assay development will take place in ANGLE's laboratories in Guildford, UK, and follows the Company's development and launch of two highly sensitive and specific DDR assays in 2023. The 6-month development phase is worth an initial £150,000 to ANGLE.
ANGLE's DDR assay has the potential to be used as a repeatable, minimally invasive means to better understand the DDR pathway to enable development of therapies capable of targeting tumour-specific DDR dependencies to preferentially kill cancer cells. The assay may also have the potential for monitoring treatment response to DDR therapies administered in combination with other cancer drugs.
ANGLE Chief Executive Officer, Andrew Newland, commented:
"This is ANGLE's second large pharma company agreement of 2024 as we look to drive a significant expansion of the pharma services business. It demonstrates the importance of CTC analysis and is a validation of ANGLE's Parsortix system. ANGLE is also working to expand its DDR work with other large pharma customers and continues to generate significant new customer interest through its business development activity."
ANGLE Chief Scientific Officer, Karen Miller commented:
"We are delighted that our expertise in CTC assay development continues to make great strides. With the increasing investigation of DNA damage response / PARP inhibitors, alone or in combination with chemotherapy or immunotherapy, there is a need for minimally invasive, robust and repeatable DDR assays. All the development work continues to add to the menu of assays owned by ANGLE that we can offer to other customers."
The DDR therapeutics market was estimated to be valued at US$5.9 billion in 2022 and is projected to reach US$10.4 billion by 2031 with a CAGR of 6.5%1. This is expected to be driven by an increase in the use of combination therapy for the treatment of drug-resistant cancers and the need for novel targeted medicines for cancer treatment. Most cancers rely on the DDR pathway to a greater extent than healthy cells. Treating patients with a DDR inhibitor alongside another cancer d
Said all along the road to commercialisation is the key issue not copy and pasting research quotes.
£150k commercial deal with Astra Zenica although modest in size may have some potential.
Glad I got in sub 12p a while back!
Shame Newland can't sell any Parsortix machines....sad really! 🤧😪😥😢😰